Invesco
LRMR icon

Invesco’s Larimar Therapeutics LRMR Stock Holding History

Invesco’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$410K Buy
134,483
+114,836
+584% +$456K ﹤0.01% 3321
2026
Q1 		$88.4K Buy
19,647
+1,246
+7% +$4.98K ﹤0.01% 3637
2025
Q4 		$70.1K Buy
18,401
+644
+4% +$2.5K ﹤0.01% 3673
2025
Q3 		$57.4K Buy
17,757
+2,553
+17% +$9.57K ﹤0.01% 3740
2025
Q2 		$43.9K Sell
15,204
-908
-6% -$2.1K ﹤0.01% 3731
2025
Q1 		$34.6K Sell
16,112
-148
-0.9% -$468 ﹤0.01% 3721
2024
Q4 		$62.9K Buy
16,260
+2,793
+21% +$18.4K ﹤0.01% 3670
2024
Q3 		$88.2K Sell
13,467
-427,820
-97% -$3.44M ﹤0.01% 3632
2024
Q2 		$3.2M Buy
441,287
+429,471
+3,635% +$3.29M ﹤0.01% 2389
2024
Q1 		$89.7K Sell
11,816
-442
-4% -$3.44K ﹤0.01% 3758
2023
Q4 		$55.8K Buy
+12,258
New +$41.4K ﹤0.01% 3743
2019
Q1 		– Sell
-1,282
Closed -$76K – 3768
2018
Q4 		$76K Buy
+1,282
New +$127K ﹤0.01% 3673
2016
Q1 		– Sell
-3,220
Closed -$243K – 3732
2015
Q4 		$243K Buy
3,220
+47
+1% +$7.55K ﹤0.01% 3522
2015
Q3 		$1.22M Buy
3,173
+3,161
+26,342% +$1.43M ﹤0.01% 2808
2015
Q2 		$5K Buy
+12
New +$5.02K ﹤0.01% 4205

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Invesco's LRMR Position: Q2 2026 in Review

Invesco increased its Larimar Therapeutics (LRMR) stake by 584% in Q2 2026, buying an estimated $456K and bringing the position to 134,483 shares worth $410K. The position accounts for ﹤0.01% of the portfolio, ranked #3321.

Invesco first reported a position in LRMR in Q2 2015 and has held it in 15 quarters since. The position peaked at $3.2M in Q2 2024. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Invesco held 134,483 shares of Larimar Therapeutics worth $410K as of Q2 2026.
  • Invesco bought 114,836 Larimar Therapeutics shares in Q2 2026, an estimated $456K.
  • Larimar Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3321 holding.
  • Invesco first reported a position in Larimar Therapeutics in Q2 2015 and has held it in 15 quarters since.
  • Invesco's Larimar Therapeutics position peaked at $3.2M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.